Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up.
Amgen and German biotech company Immatics have struck a deal potentially worth more than $1 billion, focused on a new generation of bispecific antibody cancer therapies.
Seismic Therapeutic has raised $121 million in second-round financing that will be used to take its two lead drugs through early-stage clinical testing.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio